Abstract
Objective
The aim of this study was to investigate long-term immunological changes after the treatment of Graves’ disease (GD) with thyroid arterial embolization and the effect of thyroid arterial embolization on the body’s immunological functions.
Materials and methods
Forty-one patients with clinically and laboratorily ascertained GD were treated with thyroid arterial embolization and followed up for 3–54 months following embolization. Prior to embolization and at 1, 3, 6, 12, and 36 months following embolization, thyroid autoimmune antibodies were tested respectively, including thyroid stimulating antibody (TSAb), thyrotropin antibody (TRAb), thyroglobulin antibody (TGAb), and thyroid microsomal antibody (TMAb), as well as subgroup lymphocytes of CD16+CD56+, CD19+, CD3+, CD3+CD4+ and CD3+CD8+. The autoimmune status of GD patients prior to embolization and the dynamic changes of the immunological function after embolization were analyzed.
Results
The therapy of thyroid arterial embolization could effectively decrease the activity/titer and positive rate of TRAb and the ratio of CD4+/ CD8+ to normal levels at 6 months following embolization, while the ratio of CD3+CD8+ increased gradually to normal level at 1 year following embolization. In patients with recurrence, TSAb and TRAb remained at a higher level, while the rate of CD3+CD8+ and the ratio of CD4+/CD8+ were not statistically significantly different from those before embolization.
Conclusion
Immunological functional disorder exists in GD patients. The treatment method of thyroid arterial embolization can effectively resume the basic immunological function to normal range while patients with recurrence have no significant improvement, suggesting that thyroid arterial embolization has an effective role in adjusting the immunological function.
Similar content being viewed by others
References
Boger MS, Perrier ND. Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin North Am 2004;84:849–74.
Cunnien AJ, Hay ID, Gorman CA, Offord KP, Scanlon PW. Radioiodine-induced hypothyroidism in Graves’ disease: factors associated. J Nucl Med 1982;23:978–83.
Pearce EN, Braverman LE. Hyperthyroidism: advantages and disadvantages of medical therapy. Surg Clin North Am 2004;84:833–47.
Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest 2003;111:1897–904.
Mitsiades N, Poulaki V, Mitsiades CS, Koutras DA, Chrousos GP. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends Endocrinol Metab: TEM 2001;12:384–90.
Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003;24:802–35.
Weetman AP. Grave’s disease 1835–2002. Horm Res 2003;59(Suppl 1):114–8.
Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, et al. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospective study. Endocr J 2007;54:713–20.
Okamoto T, Iihara M, Obara T. Management of hyperthyroidism due to Graves’ and nodular diseases. World J Surg. 2000;24:957–61.
Feldt-Rasmussen U, Glinoer D, Orgiazzi J. Reassessment of antithyroid drug therapy of Graves’ disease. Annu Rev Med 1993;44:323–34.
Toft AD, Weetman AP. Screening for agranulocytosis in patients treated with antithyroid drugs. Clin Endocrinol 1998;49:271.
Weetman AP. Graves’ disease. N Engl J Med 2000;343:1236–48.
Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur Jo Endocrinol 2005;153:489–98.
Izumi Y, Takeoka K, Amino N. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves’ thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves’ disease. Endocr J 2005;52:493–7.
Levy EG. Treatment of Graves’ disease: the American way. Baillière’s Clin Endocrinol Metab 1997;11:585–95.
Galkin EV, Grakov BS, Protopopov AV. First clinical experience of radio-endovascular functional thyroidectomy in the treatment of diffuse toxic goiter. Vestn Rentgenol Radiol. 1994;29–35.
Xiao H, Zhuang W, Wang S, Yu B, Chen G, Zhou M, et al. Arterial embolization: a novel approach to thyroid ablative therapy for Graves’ disease. J Clin Endocrinol Metab 2002;87:3583–9.
Zhao W, Gao BL, Yang HY, Li H, Song DP, Xiang ST, et al. Thyroid arterial embolization to treat Graves’ disease. Acta Radiol 2007;48:186–92.
Trowbridge FL, Matovinovic J, McLaren GD, Nichaman MZ. Iodine and goiter in children. Pediatrics 1975;56:82–90.
Dworkin HJ, Meier DA, Kaplan M. Advances in the management of patients with thyroid disease. Semin Nucl Med 1995;25:205–20.
Lazarus JH. Guidelines for the use of radioiodine in the management of hyperthyroidism: a summary. Prepared by the radioiodine audit subcommittee of the royal college of physicians committee on diabetes and endocrinology, and the research unit of the royal college of physicians. J R Coll Physicians Lond 1995;29:464–9.
Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. Jama 1995;273:808–12.
Dai WX, Zhang JD, Zhan SW, Xu BZ, Jin H, Yao Y, et al. Retrospective analysis of 18 cases of antithyroid drug (ATD)-induced agranulocytosis. Endocr J 2002;49:29–33.
McIver B, Morris JC. The pathogenesis of Graves’ disease. Endocrinol Metab Clin N Am 1998;27:73–89.
Abe Y. Apoptosis in the pathogenesis of autoimmune thyroid disease. Nippon Rinsho 1999;57:1717–22.
Giovanella L, Ceriani L, Garancini S. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO). Q J Nucl Med 2001;45:115–9.
Fisfalen ME, Palmer EM, Van Seventer GA, Soltani K, Sawai Y, Kaplan E, et al. Thyrotropin-receptor and thyroid peroxidase-specific T cell clones and their cytokine profile in autoimmune thyroid disease. J Clin Endocrinol Metab 1997;82:3655–63.
Li L, Paul S, Tyutyulkova S, Kazatchkine MD, Kaveri S. Catalytic activity of anti-thyroglobulin antibodies. J Immunol 1995;154:3328–32.
McIntosh RS, Asghar MS, Weetman AP. The antibody response in human autoimmune thyroid disease. Clin Sci (Lond) 1997;92:529–41.
Song YH, Li Y, Maclaren NK. The nature of autoantigens targeted in autoimmune endocrine diseases. Immunol Today 1996;17:232–8.
Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994;15:788–830.
Okita N, Row VV, Volpe R. Suppressor T-lymphocyte deficiency in Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 1981;52:528–33.
Tamai H, Uno H, Hirota Y, Matsubayashi S, Kuma K, Matsumoto H, et al. Immunogenetics of Hashimoto’s and Graves’ diseases. J Clin Endocrinol Metab 1985;60:62–6.
Acknowledgment
This study was supported by the Association of Science and Technology of Yunnan Province (2002C0012Z), China.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhao, W., Gao, BL., Jin, CZ. et al. Long-Term Immunological Study in Graves’ Disease Treated with Thyroid Arterial Embolization. J Clin Immunol 28, 456–463 (2008). https://doi.org/10.1007/s10875-008-9209-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-008-9209-0